Janus Henderson Group PLC Cuts Stock Holdings in Cencora, Inc. (NYSE:COR)

Janus Henderson Group PLC cut its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 10.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 368,670 shares of the company's stock after selling 44,767 shares during the period. Janus Henderson Group PLC owned 0.19% of Cencora worth $82,834,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Jefferies Financial Group Inc. boosted its position in shares of Cencora by 61.6% during the fourth quarter. Jefferies Financial Group Inc. now owns 9,375 shares of the company's stock worth $2,106,000 after acquiring an additional 3,574 shares during the last quarter. Humankind Investments LLC lifted its stake in Cencora by 4.1% in the 4th quarter. Humankind Investments LLC now owns 2,233 shares of the company's stock worth $502,000 after purchasing an additional 88 shares in the last quarter. Gen Wealth Partners Inc boosted its holdings in shares of Cencora by 28.8% during the 4th quarter. Gen Wealth Partners Inc now owns 3,291 shares of the company's stock valued at $740,000 after purchasing an additional 735 shares during the last quarter. Gotham Asset Management LLC boosted its holdings in shares of Cencora by 15.1% during the 4th quarter. Gotham Asset Management LLC now owns 58,639 shares of the company's stock valued at $13,175,000 after purchasing an additional 7,711 shares during the last quarter. Finally, Ethic Inc. grew its position in shares of Cencora by 11.0% during the fourth quarter. Ethic Inc. now owns 9,536 shares of the company's stock valued at $2,143,000 after purchasing an additional 945 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Insider Transactions at Cencora

In other news, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. The trade was a 9.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the sale, the chairman now owns 315,913 shares of the company's stock, valued at $89,027,442.53. The trade was a 4.41% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,223 shares of company stock worth $13,580,967. 10.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages recently commented on COR. UBS Group increased their price target on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Bank of America raised their target price on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. JPMorgan Chase & Co. upped their price target on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Wells Fargo & Company increased their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. Finally, StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $301.18.

Cencora Trading Up 1.5%

Shares of COR stock traded up $4.27 during trading hours on Friday, reaching $290.24. 1,355,556 shares of the stock were exchanged, compared to its average volume of 1,540,600. The firm has a market capitalization of $56.28 billion, a price-to-earnings ratio of 41.29, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $309.35. The company's 50-day moving average price is $279.10 and its 200-day moving average price is $254.99. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The business had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. During the same quarter in the previous year, the business earned $3.80 earnings per share. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.76%. Cencora's payout ratio is 25.52%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.